Liraglutide

What it is

Liraglutide is a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk and approved by the FDA in 2010 for type 2 diabetes (Victoza) and in 2014 for chronic weight management (Saxenda). Liraglutide was the first GLP-1 receptor agonist approved for weight management and represented a significant clinical advance at the time, despite being subsequently surpassed in effect size by once-weekly agents.

The molecule is a 31-amino-acid synthetic peptide with 97% structural similarity to native human GLP-1, modified by attachment of a C16 fatty acid via a glutamic acid spacer at lysine 26. This modification promotes reversible albumin binding and provides a half-life of approximately 13 hours — substantially longer than native GLP-1 (1–2 minutes) but much shorter than semaglutide (~165 hours), accounting for the daily dosing requirement.

Mechanism of action

Liraglutide acts through the same GLP-1 receptor mechanism as semaglutide and other GLP-1 agonists: glucose-dependent insulin secretion from pancreatic β-cells, glucagon suppression, slowed gastric emptying, and central effects on appetite regulation through hypothalamic and brainstem pathways. The pharmacological profile is essentially the same as semaglutide; differences are primarily in pharmacokinetics and effect magnitude rather than mechanism.

Clinical use and evidence

The SCALE program established efficacy of liraglutide for chronic weight management:

• SCALE Obesity and Prediabetes: 56-week trial showing mean weight loss of 8.0% with liraglutide 3.0 mg vs. 2.6% with placebo
• SCALE Diabetes: 56-week trial in type 2 diabetes showing weight loss of 6.0% with liraglutide vs. 2.0% with placebo, with HbA1c improvements
• LEADER cardiovascular outcomes trial: 9,340 patients with established cardiovascular disease, demonstrating reduction in major adverse cardiovascular events

The cardiovascular benefit was a landmark finding for the GLP-1 class and supported subsequent label expansions for cardioprotective indication.

Why we don’t prescribe it routinely at The Tide

Liraglutide is a valid GLP-1 agonist with proven efficacy and an established cardiovascular safety profile. However, the once-weekly options (semaglutide, tirzepatide) provide several practical advantages for new patients starting GLP-1 therapy:

• Adherence: once-weekly dosing has substantially better long-term adherence than daily injection regimens
• Effect size: semaglutide 2.4 mg produces approximately twice the weight loss of liraglutide 3.0 mg in head-to-head comparison
• Tirzepatide produces even larger weight loss effects through dual GLP-1/GIP mechanism
• Patient experience: the lower injection burden of once-weekly therapy improves patient satisfaction

For new patients beginning GLP-1 therapy at The Tide, we typically prescribe semaglutide or tirzepatide. Patients already stable on liraglutide who are achieving good results and prefer to continue current therapy can do so with their current physician. Patients who have not achieved goals on liraglutide may benefit from transition to once-weekly alternatives, which we can manage in our practice.

Side effects and contraindications

The side effect and contraindication profile parallels other GLP-1 agonists: gastrointestinal effects during titration (nausea, vomiting, diarrhea), pancreatitis risk, gallbladder events, and concerns about medullary thyroid cancer based on rodent data. Contraindicated in personal/family history of medullary thyroid cancer, MEN-2 syndrome, history of pancreatitis, and pregnancy.